Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Barbara R. Haight"'
Publikováno v:
Harm Reduction Journal, Vol 20, Iss 1, Pp 1-13 (2023)
Abstract Background BUP-XR (SUBLOCADE®) is the first buprenorphine extended-release subcutaneous injection approved in the USA for monthly treatment of moderate-to-severe opioid use disorder (OUD). Among patients with OUD, those who inject or use hi
Externí odkaz:
https://doaj.org/article/c923bb74f49c412ea6b467cd77d997da
Autor:
Vishaal Mehra, James L. Andersen, Michael J. Biunno, Jelena Kunovac, Walter Ling, Barbara R. Haight, Saleem Ishaque, David R. Hassman, Gregory Seal, Scott Daniel Segal, Amanda S. Garofalo, Jesse M. Carr, Valentin Isacesu, Rakesh Ranjan, Ricky Stuart Mofsen, Otto R. Dueno, Kent Steven Hoffman, Paul J. Fudala, Brent Boyett, Shishuka Malhotra, Lawrence S. Levinson, Céline M. Laffont, Peter Paul Ventre, Eduardo Cifuentes, Sandra Daniela Duarte-Sckell, Scott Robert Bartley, Genie L. Bailey, Richard D. Knapp, Gita G. Pujari, Kyle M. Kampman, Rajinder Shiwach, Christian Heidbreder, Vijay R Nadipelli, Daniel Rutrick, Y Zhao, Rishi Kakar, Katharina Wiest, Marvin Lane Peyton, David P. Walling, Susan M Learned, Joseph A. Kwentus, Amit K. Vijapura, Haydn Mikel Thomas, Boyde J. Harrison, Mark K. Greenwald, George Konis
Publikováno v:
The Lancet. 393:778-790
RBP-6000, referred to as BUP-XR (extended-release buprenorphine), is a subcutaneously injected, monthly buprenorphine treatment for opioid use disorder. BUP-XR provides sustained buprenorphine plasma concentrations to block drug-liking of abused opio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d956456416ef2fa898c563ec73fed86b
https://doi.org/10.1016/s0140-6736(18)32259-1
https://doi.org/10.1016/s0140-6736(18)32259-1
Autor:
Barbara R. Haight, Norma Lynn Fox, Sunita Shinde, Anne Andorn, David R. Hassman, Paul J. Fudala, Susan M Learned, Christian Heidbreder, Vijay R Nadipelli, Daniel Rutrick, Y Zhao
Publikováno v:
Journal of Clinical Psychopharmacology
Supplemental digital content is available in the text.
Background BUP-XR (RBP-6000 or SUBLOCADE) is the first Food and Drug Administration–approved subcutaneously administered monthly extended-release buprenorphine medication for the treatment
Background BUP-XR (RBP-6000 or SUBLOCADE) is the first Food and Drug Administration–approved subcutaneously administered monthly extended-release buprenorphine medication for the treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e7f24f63585d4b3e1294bd57656ffd4
https://pubmed.ncbi.nlm.nih.gov/32282418
https://pubmed.ncbi.nlm.nih.gov/32282418
Autor:
Paul J. Fudala, Study Investigators, Walter Ling, Amanda S. Garofalo, Susan M Learned, Barbara R. Haight, Y Zhao, Christian Heidbreder, Vijay R Nadipelli, Céline M. Laffont, Mark K. Greenwald
Publikováno v:
SSRN Electronic Journal.
Background: RBP-6000 is a subcutaneously injected, extendedrelease, monthly treatment for opioid use disorder (OUD). RBP 6000 addresses potential limitations of other OUD treatments by delivering sustained buprenorphine plasma concentrations to block
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ec43f9ac697af44639f3ba4dd54fd6c
https://doi.org/10.2139/ssrn.3228895
https://doi.org/10.2139/ssrn.3228895
Autor:
Alexander M. Walker, Jack G. Modell, Barbara R. Haight, J. Alexander Cole, Irene S. Cosmatos, Joan M. Stoler
Publikováno v:
Pharmacoepidemiology and Drug Safety. 16:474-484
Purpose Reports from the GlaxoSmithKline Bupropion Pregnancy Registry suggested an increase in cardiovascular defects following exposure to bupropion during pregnancy. We conducted a study of congenital malformations among infants born to women expos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df70a5b3c287f049c52ea6c0f33c6de2
https://doi.org/10.1002/pds.1296
https://doi.org/10.1002/pds.1296
Autor:
April H Thompson, Jack G. Modell, Barbara R. Haight, J. Andrew Johnston, Michael E. Thase, Anita H. Clayton
Publikováno v:
Journal of Clinical Psychopharmacology. 26:482-488
In this double-blind, multicenter study, bupropion XL, a norepinephrine-dopamine reuptake inhibitor, and venlafaxine XR, a serotonin-norepinephrine reuptake inhibitor, were compared with regard to sexual functioning, efficacy, and tolerability. A tot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11abbc5f22a73d1fe5c292d121a1f128
https://doi.org/10.1097/01.jcp.0000239790.83707.ab
https://doi.org/10.1097/01.jcp.0000239790.83707.ab
Publikováno v:
Biological Psychiatry. 59:203-210
Incomplete symptom remission and sexual side effects are common problems for which bupropion often is added to treatment with selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs and SNRIs) for patients with major depressive di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c59f71c1cfdfa1b021bbbff6e1ba86a9
https://doi.org/10.1016/j.biopsych.2005.06.027
https://doi.org/10.1016/j.biopsych.2005.06.027
Autor:
Carol B. Rockett, April E. Harriett, Michael E. Thase, Melinda Mitton, Susan VanMeter, Nathalie Richard, Younghua Wang, Barbara R. Haight, Jack G. Modell
Publikováno v:
The Journal of Clinical Psychiatry. 66:974-981
Background: Although it is widely believed tha the various classes of antidepressants are equally effective, clinically meaningful differences may be obscured in individual studies because of a lack of statistical power. The present report describes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::409a2b565d7a3bca81bdf382844b6aa7
https://doi.org/10.4088/jcp.v66n0803
https://doi.org/10.4088/jcp.v66n0803
Autor:
Alok Krishen, Barbara R. Haight, Marty C. Johnson, Thomas Hunt, Richard J. Fleck, Jack G. Modell, Michael E. Thase
Publikováno v:
Journal of clinical psychopharmacology. 28(3)
The effects of bupropion on blood pressure and heart rate were evaluated in a double-blind, placebo-controlled study of community volunteers with untreated mild (stage 1) hypertension (systolic blood pressure [SBP], 140-159 mm Hg, and/or diastolic bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae9534da49fe2bc6838e9e28f404705b
https://pubmed.ncbi.nlm.nih.gov/18480687
https://pubmed.ncbi.nlm.nih.gov/18480687
Autor:
Carol B. Rockett, Barbara R. Haight, James F. Pradko, Stephen M. Stahl, Jack G. Modell, Susan Learned-Coughlin
BACKGROUND: The neurochemical and biological effects of antidepressant medications have become better defined over the last decade. When the anti-depressant bupropion was introduced in the United States in 1989, the specific pharmacologic basis of it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1bb41e69e0d20a7da32dd649a0461dd
https://europepmc.org/articles/PMC514842/
https://europepmc.org/articles/PMC514842/
